Cited by 190Angiogenesis and VEGF in CancerCancer Immunotherapy and BiomarkersCancer Cells and Metastasis

The DOI matches its Crossref record; 171 of the 172 references it cites were found in a registry or an index.

Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy

Open access

Choi, Yechan, Jung, Keehoon·2023·Experimental & Molecular Medicine

DOI 10.1038/s12276-023-01114-wPMC PMC10689787

Open this paper in CoChat — free account Open PDF

Abstract

Solid tumors are complex entities that actively shape their microenvironment to create a supportive environment for their own growth. Angiogenesis and immune suppression are two key characteristics of this tumor microenvironment. Despite attempts to deplete tumor blood vessels using antiangiogenic drugs, extensive vessel pruning has shown limited efficacy. Instead, a targeted approach involving the judicious use of drugs at specific time points can normalize the function and structure of tumor vessels, leading to improved outcomes when combined with other anticancer therapies. Additionally, normalizing the immune microenvironment by suppressing immunosuppressive cells and activating immunostimulatory cells has shown promise in suppressing tumor growth and improving overall survival. Based on these findings, many studies have been conducted to normalize each component of the tumor microenvironment, leading to the development of a variety of strategies. In this review, we provide an overview of the concepts of vascular and immune normalization and discuss some of the strategies employed to achieve these goals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s12276-023-01114-w

Cites

171 of 171 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Vascular normalization: Restoring vascular integrity to enhance oxygenation and therapeutic drug delivery in tumor vasculature. a Comparison of vascular normalization with current therapies using AATs. Tumors exhibit abnormal vasculature, characterized by irregularly shaped endothelial cells, sparse pericyte coverage, and compression by tumor cells and their extracellular matrices, resulting in poorly perfused vessels (middle panel). Current antiangiogenic therapies, mainly aimed at depleting the tumor vasculature, often lead to excessive vessel pruning, causing hypoxia and limited drug delivery (left panel). Vascular normalization strategies aim to restore vascular integrity, improving oxygenation and enhancing the delivery of therapeutic drugs (right panel). b Various vascular normalization methods. Vascular normalization can be induced by targeting VEGF signaling or Ang–Tie signaling in endothelial cells or oncogenic signaling in cancer cells. Immune checkpoint blockade can induce vascular normalization through the function of CD8+ or CD4 + T cells and the accumulation of eosinophils. AAT, antiangiogenic therapy; IFP, interstitial fluid pressure; CAF, cancer-associated fibroblast; ECM, extracellular matrix; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; PLCγ, phospholipase γ; PI3K, phosphoinositide 3-kinase; Ang2, angiopoietin 2; EGFR, epidermal growth factor receptor.CC BY · PubMed Central

Fig. 2 Immune normalization: Modulating the tumor immune microenvironment to suppress immunosuppression and recruit antitumoral immune cells. Tumors employ mechanisms to enhance immunosuppression, including recruiting immunosuppressive leukocytes and suppressing the function of antitumoral immune cells. Chemotaxis of classical monocytes (CMs) is facilitated by the CCL2–CCR2 axis, and these CMs secrete cytokines such as IL-6, that promote tumor metastasis and therapy resistance. Tumors secrete CX3CL1, recruiting nonclassical monocytes (NCMs) that, in turn, can recruit neutrophils via the CXCL5–CXCR2 axis. Both CMs and NCMs secrete immunosuppressive cytokines, including IL-10. M2-like TAMs further suppress the antitumoral immune response by secreting cytokines such as IL-4. Immune checkpoints employed by tumors dampen the function of effector T cells. Strategies for immune normalization include inhibiting monocyte recruitment using anti-CCL2 antibodies/siRNAs, CXCR4 blockers, or CCR2 inhibition. Enhancing effector T-cell function can be achieved through cancer vaccines or immune checkpoint blockade (ICB). Additionally, oncolytic viruses can target tumor cells, inducing their lysis and recruiting antitumoral immune cells. NK, natural killer; CM, classical monocyte; NCM, nonclassical monocyte; TAM, tumor-associated macrophage; ROS, reactive oxygen species; ICB, immune checkpoint blockade; GM-CSF, granulocyte-macrophage colony-stimulating factor.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: The Oncolytic Virus in Cancer Diagnosis and Treatment
Cao, G., He, X., Sun, Q., Chen, S., Wan, K. M., Xu, X., Feng, X., Li, P., Chen, B., & Xiong, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01786 · Cited by 109
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 3×
“Moreover, in certain solid tumors, cancer-associated ﬁ broblasts (CAFs) and their production of ECM components exert compressive forces on tumor vessels, exacerbating the hypoxia 24 .”
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Acute Myeloid Leukemia
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,222
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor Angiogenesis
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 2,011
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
PD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 1,602
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,600
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Therapeutic cancer vaccines
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,493
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,414
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Hypoxic control of metastasis
Rankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340 · cited 1×
“…cell populations 25 and pathological CAFs 26 – 28 , hampers the cytotoxic activity of tumor-in ﬁ ltrating effector T cells, enables immune evasion by cancer cells 8,29 , promotes metastasis 30 , and diminishes the ef ﬁ cacy of radiotherapy 31 , chemotherapy 32 , and immunotherapy 33 .”
Background
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
The Biology of Chronic Myeloid Leukemia
Faderl, S. H., Talpaz, M., Estrov, Z. E., O'Brien, S. M., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,322
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Therapeutic cancer vaccines
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,192
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,135
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
The Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044 · cited 2×
“Moreover, in certain solid tumors, cancer-associated ﬁ broblasts (CAFs) and their production of ECM components exert compressive forces on tumor vessels, exacerbating the hypoxia 24 .”
Background
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 1,007
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 860
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Nywening, T. M., Wang‐Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 847
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 844
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 832
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Taal, W., Oosterkamp, H. M., Walenkamp, A., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D. H., Vos, F. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 784
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 716
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M., Wyckoff, J. B., Mertz, K. D., Varga, Z., Junt, T., & Bentires‐Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 700
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 674
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 670
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D. H., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 631
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy
Huang, L., Li, Y., Du, Y., Zhang, Y., Wang, X., Ding, Y., Yang, X., Meng, F., Tu, J., Luo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12771-9 · Cited by 608
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J. C., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 601
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Demaria, O., Gassart, A. D., Coso, S., Gestermann, N., Domizio, J. D., Flatz, L., Gaide, O., Michielin, O. A., Hwu, P., Petrova, T. V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512832112 · Cited by 585
The impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 583
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 557
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 545
Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity
Swartz, M. A., & Lund, A. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3186 · Cited by 544
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2009) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 526
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljković, M. D., & Waldmann, T. A. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 523
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
c-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J. G., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 506
Immunotherapy: Reshape the Tumor Immune Microenvironment
Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500
Patrolling monocytes control tumor metastasis to the lung
Hanna, R. N., Cekic, C., Sağ, D., Tacke, R., Thomas, G. D., Nowyhed, H. N., Herrley, E., Rasquinha, N., McArdle, S., Wu, R., et al. (2015) · Science · doi:10.1126/science.aac9407 · Cited by 497
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K. H., Bono, P., & Alitalo, K. K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 489
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies
Sung, Y., Jin, P.-R., Chu, L., Hsu, F., Wang, M.-R., Chang, C. S., Chiou, S.-J., Qiu, J.-T. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 459
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kiéda, C., Janji, B., & Chouaı̈b, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 420
Regulation of innate and adaptive immunity by Notch
Radtke, F., MacDonald, H. R., & Tacchini‐Cottier, F. (2013) · Nature reviews. Immunology · doi:10.1038/nri3445 · Cited by 416
Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo
Xin, X., Yang, S., Ingle, G. S., Zlot, C. H., Rangell, L. K., Kowalski, J., SCHWALL, R. H., Ferrara, N., & Gerritsen, M. E. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64058-8 · Cited by 397
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 376
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Cassier, P. A., Italiano, A., Gomez‐Roca, C., Tourneau, C. L., Toulmonde, M., Cannarile, M. A., Ries, C. H., Brillouet, A., Müller, C., Jegg, A.-M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00132-1 · Cited by 374
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Self-citation
Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“…cell populations 25 and pathological CAFs 26 – 28 , hampers the cytotoxic activity of tumor-in ﬁ ltrating effector T cells, enables immune evasion by cancer cells 8,29 , promotes metastasis 30 , and diminishes the ef ﬁ cacy of radiotherapy 31 , chemotherapy 32 , and immunotherapy 33 .”
Background
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H. P. M. W., Guetens, G., Boeck, G. D., Verbeken, E. K., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 333
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J., Han, S.-U., Cho, H., Jennings, B. A., Gerrard, B., Dean, M. C., Schmidt, L. S., Zbar, B., & Woude, G. F. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 330
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A., Hu‐Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 320
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 320
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A. K., Komar, C. A., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben‐Josef, E., & Beatty, G. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 319
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 317
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Peterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Self-citation
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Yang, H., Lee, W. S., Kong, S. J., Kim, C. G., Kim, J. H., Chang, S. K., Kim, S., Kim, G., Chon, H. J., & Kim, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125413 · Cited by 316
Nitric Oxide in Vascular Biology
Walford, G., & Loscalzo, J. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00345.x · Cited by 302
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Zheng, M., Huang, J., Tong, A., & Yang, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.007 · Cited by 302
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera‐Troise, I., & Yancopoulos, G. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2130 · Cited by 297
Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization
Dings, R. P. M., Loren, M. L., Heun‐Johnson, H., McNiel, E. A., Griffioen, A. W., Mayo, K. H., & Griffin, R. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2441 · Cited by 287
Chronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280
IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma
Long, K. B., Gladney, W. L., Tooker, G. M., Graham, K. L., Fraietta, J. A., & Beatty, G. L. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1032 · Cited by 275
Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects
Rayes, R. F., Mouhanna, J. G., Nicolau, I. A., Bourdeau, F., Giannias, B., Rousseau, S., Quail, D. F., Walsh, L. A., Sangwan, V., Bertos, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128008 · Cited by 265
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
Rak, J. W., Croix, B. D. S., & Kerbel, R. S. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199502000-00001 · Cited by 244
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways
Sørensen, B. S., & Horsman, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00562 · Cited by 241
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05351-1 · Cited by 240
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231
High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis
Yuan, Z.-Y., Luo, R., Peng, R., Wang, S., & Xue, C. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s61838 · Cited by 214
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25 + Foxp3 + regulatory T cells
Benkhoucha, M., Santiago‐Raber, M., Schneiter, G., Chofflon, M., Funakoshi, H., Nakamura, T., & Lalive, P. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912437107 · Cited by 210
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Papadopoulos, K. P., Gluck, L., Martin, L. P., Olszanski, A. J., Tolcher, A. W., Ngarmchamnanrith, G., Rasmussen, E., Amore, B. M., Nagorsen, D., Hill, J. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3261 · Cited by 209
Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies
Khouzam, R. A., Brodaczewska, K. K., Filipiak-Duliban, A., Zeinelabdin, N. A., Buart, S., Szczylik, C. A., Kiéda, C., & Chouaı̈b, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 208
Amelioration of sepsis by TIE2 activation–induced vascular protection
Han, S., Lee, S.-J., Kim, K. E., Lee, H. S., Oh, N., Park, I., Ko, E., Oh, S. J., Lee, Y.-S., Kim, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9260 · Cited by 203
Vascular regulation of antitumor immunity
Munn, L. L., & Jain, R. K. (2019) · Science · doi:10.1126/science.aaw7875 · Cited by 194
Tumor microenvironment and radioresistance
Suwa, T., Kobayashi, M., Nam, J., & Harada, H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00640-9 · Cited by 186
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 179
Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
Nasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C., Schadendorf, D., Thurston, G., Fiedler, U., & Augustin, H. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3030 · Cited by 177
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Self-citation
Nelfinavir Down-regulates Hypoxia-Inducible Factor 1α and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy
Pore, N., Gupta, A., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. M., Koch, C. J., Hahn, S. M., & Maity, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1239 · Cited by 154
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
Ali, O. A., Lewin, S. A., Dranoff, G., & Mooney, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0126 · Cited by 150
Sipuleucel-T
Higano, C. S., Small, E. J., Schellhammer, P. F., Yasothan, U., Gubernick, S. I., Kirkpatrick, P. N., & Kantoff, P. W. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3220 · Cited by 147
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S. K., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 146
Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner
Papageorgis, P., Polydorou, C., Mpekris, F., Voutouri, C., Agathokleous, E. A., Kapnissi‐Christodoulou, C. P., & Stylianopoulos, T. (2017) · Scientific Reports · doi:10.1038/srep46140 · Cited by 140
Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
Self-citation
Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients
Ong, T., McClintock, D. E., Kallet, R. H., Ware, L. B., Matthay, M. A., & Liu, K. D. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181eaa5bf · Cited by 136
Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer
Patel, N. S., Dobbie, M. S., Rochester, M. A., Steers, G., Poulsom, R., Monnier, K. L., Cranston, D., Li, J., & Harris, A. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0285 · Cited by 133
Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy
Cerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S. M., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 124
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Munnink, T. H. O., Oosting, S. F., van Scheltinga, A. G. T. T., Gietema, J. A., Garbacik, E. T., Timmer‐Bosscha, H., Hooge, M. N. L., Schroder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 124
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L. M., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 124
Delta-like 4/Notch Signaling and Its Therapeutic Implications
Yan, M., & Plowman, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1393 · Cited by 121
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 113
PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer
Kim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 102
Self-citation
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer
Whatcott, C. J., Han, H., & Hoff, D. D. V. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000140 · Cited by 96
A novel Notch ligand, Dll4, induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer
Yan, X., Sarmiento, U. M., Sun, Y. S., Huang, G. N., Guo, J., Juan, T., Van, G. Y., Qi, M., Scully, S. A., Senaldi, G., et al. (2001) · Blood · doi:10.1182/blood.v98.13.3793 · Cited by 96
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Cascone, T., Xu, L., Lin, H. Y., Liu, W., Tran, H. T., Liu, Y., Howells, K., Haddad, V., Hanrahan, E. O., Nilsson, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3216 · Cited by 92
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Zhou, Q. S., & Gallo, J. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-088 · Cited by 91
H-Ras Regulates Angiogenesis and Vascular Permeability by Activation of Distinct Downstream Effectors
Serban, D., Leng, J., & Cheresh, D. A. (2008) · Circulation Research · doi:10.1161/circresaha.107.169664 · Cited by 89
Tumor regionalization after surgery: Roles of the tumor microenvironment and neutrophil extracellular traps
Kwak, S.-B., Kim, S. J., Kim, J., Kang, Y.-L., Ko, C. W., Kim, I., & Park, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00784-2 · Cited by 89
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P., Delgoffe, G. M., & Curran, M. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound
Ho, Y.-J., Chu, S.-W., Liao, E., Fan, C., Chan, H., Wei, K., & Yeh, C. (2019) · Theranostics · doi:10.7150/thno.37750 · Cited by 87
Normalization of Tumour Blood Vessels Improves the Delivery of Nanomedicines in a Size-Dependent Manner
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2020) · doi:10.1201/9780429399039-10 · Cited by 81
Common features of chromatin in aging and cancer: cause or coincidence?
Zane, L. K., Sharma, V., & Misteli, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.001 · Cited by 79
Immunogenic cell death in cancer immunotherapy
Choi, M., Shin, J., Lee, C.-E., Chung, J.-Y., Kim, M., Yan, X., Yang, W., & Cha, J. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0024 · Cited by 79
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
Petty, A. J., Owen, D. H., Yang, Y., & Huang, X. (2021) · Cancers · doi:10.3390/cancers13215318 · Cited by 78
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Davar, D., Ding, F., Saul, M. I., Sander, C., Tarhini, A. A., Kirkwood, J. M., & Tawbi, H. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0279-5 · Cited by 76
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 76
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 75
Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells
Kubo, H., Mensurado, S., Gonçalves‐Sousa, N., Serre, K., & Silva‐Santos, B. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0082 · Cited by 73
The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Moyal, E. C., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., & Bernhard, E. J. (2001) · PubMed · Cited by 71
Mini‐review: Overcoming tumor‐intrinsic resistance to immune effector function
Ganß, R., Arnold, B., & Hämmerling, G. J. (2004) · European Journal of Immunology · doi:10.1002/eji.200425474 · Cited by 70
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Delmas, C., End, D. W., Rochaix, P., Favre, G., Toulas, C., & Moyal, E. C. (2003) · PubMed · Cited by 70
Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment
Jeong, J., Suh, Y., & Jung, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01817 · Cited by 66
Self-citation
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
Beyar‐Katz, O., & Gill, S. I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3016 · Cited by 65
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes
Hyeon, D. Y., Nam, D., Han, Y., Kim, D. K., Kim, G., Kim, D., Bae, J., Back, S., Mun, D., Madar, I. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00479-7 · Cited by 57
Self-citation
Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics
Cohen, L., Pieterman, E. J., van Leeuwen, R. E. W., Overhand, M., Burm, B. E. A., van der MAREL, G. A., & BOOM, J. H. V. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00386-5 · Cited by 56
CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
Palma, M. D., & Jain, R. K. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.015 · Cited by 53
DLL1 orchestrates CD8 + T cells to induce long-term vascular normalization and tumor regression
Zhang, N., Yin, R., Zhou, P., Liu, X., Fan, P., Qian, L., Li, D., Zhang, C., Zheng, X., Deng, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020057118 · Cited by 50
Toward Normalization of the Tumor Microenvironment for Cancer Therapy
Zheng, J., & Gao, P. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419862352 · Cited by 42
Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
Kirkwood, J. M., Resnick, G. D., & Cole, B. F. (1997) · PubMed · Cited by 35
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kiéda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
Immunology and Immunotherapy of Chronic Myeloid Leukemia
Ilander, M. M., Hekim, C., & Mustjoki, S. M. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0190-1 · Cited by 30
Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization
Zhang, J., Qin, H., Wang, L., Liang, L., Zhao, X., Cai, W., Wei, Y., Wang, C., & Han, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.008 · Cited by 28
Inhibition of Tumor Angiogenesis and Tumor Growth by the DSL Domain of Human Delta-Like 1 Targeted to Vascular Endothelial Cells
Zhao, X., Dou, G., Wang, L., Liang, L., Tian, D., Cao, X., Qin, H., Wang, C., Zhang, P., & Han, H. (2013) · Neoplasia · doi:10.1593/neo.13550 · Cited by 25
Role of reactive oxygen species in regulating 27-hydroxycholesterol-induced apoptosis of hematopoietic progenitor cells and myeloid cell lines
Woo, S.-Y., Lee, H., Park, S. M., Choi, H.-S., Kim, J., Kwon, M., Sohn, J., Nam, J. H., Kim, H., Song, P., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05360-0 · Cited by 21
MarcoPolo: a method to discover differentially expressed genes in single-cell RNA-seq data without depending on prior clustering
Kim, C., Lee, H., Jeong, J., Jung, K., & Han, B. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac216 · Cited by 16
Self-citation
Tumor-Infiltrating Neutrophils and Non-Classical Monocytes May Be Potential Therapeutic Targets for HER2negative Gastric Cancer
Jeong, J., Kim, D. K., Park, J., Park, D. J., Lee, H., Yang, H., Kong, S., & Jung, K. (2021) · Immune Network · doi:10.4110/in.2021.21.e31 · Cited by 14
Self-citation
Vascular normalization: a real benefit?
Ribatti, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1683-z · Cited by 14
Novel endogenous endoplasmic reticulum transmembrane protein SURF4 suppresses cell death by negatively regulating the STING‐STAT6 axis in myeloid leukemia
Kim, J., Lee, H., Hong, C. M., Nam, J. H., Yeo, H. J., Cho, W. H., Kim, H., Hong, C., Kim, Y. H., & Lee, D. (2022) · 癌症：英文版 · doi:10.1002/cac2.12390 · Cited by 13
MRI Assessment of Angiogenesis Inhibitor Sunitinib's Influence on Tumor Oxygenation to Identify an Optimal Chemoradiotherapeutic Window
Batra, S., Matsumoto, S., Hyodo, F., Mitchell, J., & Krishna, M. C. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.120 · Cited by 6
Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy
Zhang, Y., Gao, J., He, Y., Qi, Z., Qian, L., Chen, W., Xu, H., Yue, Y., Mao, X., Guo, S., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5867047 · Cited by 5

Sorted by citations

Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala‐Dilke, K., & Bergers, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 216
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Transformative Impact of Nanocarrier‐Mediated Drug Delivery: Overcoming Biological Barriers and Expanding Therapeutic Horizons
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
The influence of endothelial metabolic reprogramming on the tumor microenvironment
Kane, K. M., Edwards, D. N., & Chen, J. (2024) · Oncogene · doi:10.1038/s41388-024-03228-5 · Cited by 72

See all 190

Authors: Choi, Y., & Jung, K.
Affiliations: Seoul National University (KR)
Corresponding author: Jung, Keehoon
ORCID: Jung, Keehoon
Venue: Experimental & Molecular Medicine
Publisher: Springer Science and Business Media LLC
Published: 2023-11-01
Volume: 55
Issue: 11
Pages: 2308-2319
ISSN: 1226-3613 (ISSN-L)
2092-6413
DOI: 10.1038/s12276-023-01114-w
PMC: PMC10689787
OpenAlex: W4388081006
Cited by: 188
References: 172
Citations by year: 2026: 109 · 2025: 47 · 2024: 32
FWCI: 4.97
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Experimental & Molecular Medicine (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Research Foundation
Seoul National University
National Research Foundation of Korea (2021M3A9I4026318, NRF-2021M3A9I4026318)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: tumor microenvironment, tumor vasculature normalization, angiogenesis, anti-angiogenic therapy, immunosuppression, combination cancer therapy
MeSH terms: Humans, Immunotherapy, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks